All In Biotech

Drug Trial Radar · NCT00501969

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advanced-Stage Parkinson's Disease

An Open-Label Extension to the Double-Blind SP515 (NCT00244387) Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Subjects With Advanced-Stage Idiopathic Parkinson's Disease Who Are Not Well Controlled on L-Dopa

Last checked: Nov 20, 2026Latest source record: Oct 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

395

Actual

Start

Aug 2004

Primary completion

Dec 2008

Study completion Dec 2008

Sponsor

Lead sponsor
UCB PharmaUCB
Sponsor type
Industry
First posted
Jul 17, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 31 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with advanced-stage idiopathic Parkinson's disease

Conditions

  • Advanced Stage Parkinson's Disease

Interventions

  • RotigotineDrug

    Rotigotine trans-dermal patches once daily: 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours) 50 cm2 (10 mg/24 hours) 60 cm2 (12 mg/24 hours) 70 cm2 (14 mg/24 hours) 80 cm2 (16 mg/24 hours)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Subjects With at Least One Adverse Event During This Open-label Extension StudyTime frame: five years

Locations

53 sites in 17 countries. Site status is shown where the registry gives one.

  • Site not named

    Bedford Park, Australia

  • Site not named

    Concord, Australia

  • Site not named

    Darlinghurst, Australia

  • Site not named

    East Gosford, Australia

  • Site not named

    Westmead, Australia

  • Site not named

    Innsbruck, Austria

  • Site not named

    Zagreb, Croatia

  • Site not named

    Brno, Czechia

  • Site not named

    Ostrava - Poruba, Czechia

  • Site not named

    Pardubice, Czechia

  • Site not named

    Pilsen, Czechia

  • Site not named

    Prague, Czechia

  • Site not named

    Oulu, Finland

  • Site not named

    Pori, Finland

  • Site not named

    Aix-en-Provence, France

  • Site not named

    Lille, France

  • Site not named

    Lyon, France

  • Site not named

    Aachen, Germany

  • Site not named

    Bochum, Germany

  • Site not named

    Budapest, Hungary

  • Site not named

    Miskolc, Hungary

  • Site not named

    Pécs, Hungary

  • Site not named

    Petah Tikva, Israel

  • Site not named

    Tel Aviv, Israel

  • Site not named

    Milan, Italy

  • Site not named

    Naples, Italy

  • Site not named

    Padova, Italy

  • Site not named

    Pisa, Italy

  • Site not named

    Pozzilli, Italy

  • Site not named

    Roma, Italy

  • Site not named

    Auckland, New Zealand

  • Site not named

    Christchurch, New Zealand

  • Site not named

    Wellington, New Zealand

  • Site not named

    Bergen, Norway

  • Site not named

    Stavanger, Norway

  • Site not named

    Tønsberg, Norway

  • Site not named

    Trondheim, Norway

  • Site not named

    Gdansk, Poland

  • Site not named

    Krakow, Poland

  • Site not named

    Lublin, Poland

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.